Anna‐Karin Hamberg

A PK–PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy

Anna‐Karin Hamberg, M-L Dahl, Martina Barban et al. · Clinical Pharmacology & Therapeutics · 2007 · 142 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age

Anna‐Karin Hamberg, Mia Wadelius, Jonatan D. Lindh et al. · Clinical Pharmacology & Therapeutics · 2010 · 96 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy

Peter Avery, Andrea Jorgensen, Anna‐Karin Hamberg et al. · Clinical Pharmacology & Therapeutics · 2011 · 78 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children

Anna‐Karin Hamberg, Jacob Hellman, Jonny Dahlberg et al. · BMC Medical Informatics and Decision Making · 2015 · 65 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithms

Anna‐Karin Hamberg, Lena E. Friberg, Katarina Hanséus et al. · European Journal of Clinical Pharmacology · 2013 · 43 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17